-
Dr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in India
27 Apr 2024 18:36 GMT
… -obesity drugs. Biocon, too, has joined the race as patents for some … liraglutide injection, which is losing patent protection in November. Novo Nordisk … anti-obesity medications to lose patent protection.
In India, Novo Nordisk …
-
Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & Co., Novo Nordisk, Eli Lilly and Company, Biocon
23 Apr 2024 17:00 GMT
… Eli Lilly and Company, Biocon The diabetes drugs market is … , Eli Lilly and Company, Biocon, Bristol Myers Squibb, Boehringer … , Eli Lilly and Company, Biocon, Bristol Myers Squibb, Boehringer … Executive summary
3
Regulatory and Patent Analysis
4
Key Factors …
-
India's Biocon developing its own version of Wegovy, clinical trial likely next year
18 Apr 2024 16:34 GMT
… Arabia. Semaglutide will lose patent protection in those countries … comment on patent expirations in the respective countries. Biocon will first … for their obesity treatments. Biocon has been spending roughly … to India, subject to patent expiries. Novo has so …
-
Biocon Spearheads India’s Advancement in Weight Loss Medications
11 Apr 2024 07:58 GMT
… the impending expiration of patents for some major medications. … current leading position,” stated Biocon’s Chief Executive Officer … this year. Additionally, Biocon has initiated applications with … European regulators for liraglutide.
Biocon has yet to file …
-
Generic Weight Loss Drugs Boosted by UK Approval for Biocon
08 Apr 2024 17:23 GMT
… version of liraglutide injectible, whose patent ends in November.
The … in this category to lose patent protection.
While Saxenda is … Both firms have already settled patent disputes with Novo Nordisk in … a March 27 statement by Biocon.
Biocon’s shares rose 1. …
-
Biocon leads India's push into blockbuster weight-loss drugs as patents for Saxenda, Wegovy and Ozempic set to expire
08 Apr 2024 14:09 GMT
… weight loss drugs as patents for some of the … injectible, which is losing patent protection in November. Novo … anti-obesity medications to lose patent protection. ALSO READ: Can … jackpot that drugmakers like Biocon are awaiting. Patents on Ozempic and …
-
Stocks to Watch: Wipro, Biocon, Titan, Adani Group, Voda Idea, Zee Ent, and Others
08 Apr 2024 06:38 GMT
… Apollo Hospitals in the process.
Biocon: The Kiran Mazumdar Shaw led … the obesity drugs market, as patents for the blockbuster medications start …
-
Biocon leads generic race for blockbuster weight loss drugs as patents set to expire soon
08 Apr 2024 06:03 GMT
… major Biocon is focusing on anti-obesity therapies as patents of … injectible, which is losing patent protection in November this year … the brand name Saxenda by patent holder Novo Nordisk A… in this category to lose patent protection.
Although Saxenda is …
-
Biocon Leads India Push Into Weight Loss Drugs as Patents Lapse
08 Apr 2024 01:05 GMT
… ) -- Biocon Ltd. is pivoting to anti-obesity therapies as patents for … injectible, which is losing patent protection in November. The … in this category to lose patent protection.
While Saxenda is … ’s biggest players when patents expire in the coming …
-
Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®
04 Mar 2024 08:00 GMT
…
The settlement resolves multiple parallel patent infringement proceedings in the Federal … proceedings, under Canada's Patented Medicines (Notice of Compliance) … addressing pre-entry pharmaceutical patent litigation.
Shares of Biocon Limited was last …